Trial reportCancer chemotherapy and pharmacology2015
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma.
Trial report in Cancer chemotherapy and pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Angiosarcoma: a systematic review of biomarkers in diagnosis, prognosis, and therapeutic strategies.Frontiers in oncology · 2025Pooled it
- Trial
- Review
- Role of Angiopoietins in Development of Cancer and Neoplasia Associated with Viral Infection.Cells · 2020Review
- Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma.Oncotarget · 2018Article
- Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.British journal of cancer · 2018Article
- CD31 Expression Determines Redox Status and Chemoresistance in Human Angiosarcomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Propranolol for the treatment of vascular sarcomas.Journal of experimental pharmacology · 2018Review
- Ang-2 but not Ang-1 expression in perivascular soft tissue tumors.Journal of orthopaedics · 2017Article
- Ang-1 and Ang-2 expression in angiomyolipoma and PEComa family tumors.Journal of orthopaedics · 2017Article
- Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Review
- Angiopoietin pathway gene expression associated with poor breast cancer survival.Breast cancer research and treatment · 2017Article
- Endothelial cell malignancies: new insights from the laboratory and clinic.NPJ precision oncology · 2017Article
- Advances in Age-related Macular Degeneration Understanding and Therapy.US ophthalmic review · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
introductionAngiosarcomas are rare malignant endothelial cell tumors which have up-regulation of the angiopoietin system [e.g., Tie2 and Angiopoietin 2 (Ang2)]. Trebananib is a novel agent targeting Angiopoietin 1 and Angiopoietin 2.
methodsTrebananib 30 mg/kg was administered weekly until progressive disease or unacceptable toxicity. The primary endpoint was response rate by RECIST v1.1. Correlatives included: (1) baseline tumor expression of Ang2/Tie2 by immunohistochemistry, (2) serum levels of Ang1 and Ang2, (3) pre- and post-treatment phospho-receptor tyrosine kinase and (4) MYC/FLT-4 amplification status.
resultsSixteen patients were enrolled [median age 68 years (24-91), 38 % male, median number of prior therapies 2.5 (1-7)]. No responses were observed in 12 evaluable patients. Estimated median and 12-week progression-free survival rate were 7 weeks (95 % 6-8) and 25 % (95 % CI 11-58 %), respectively. Median overall survival was 28 weeks (95 % CI 17-48). There were two (12.5 %) patients who experienced grade 3 adverse event and one (6.3 %) patient who experienced grade 4 adverse event that was considered at least possibly related to treatment.
conclusionsTrebananib was well tolerated. Lack of response in the first stage of a Simon 2 stage design led to closure of this study. Prolonged PFS was observed in four pts, lasting 3.4-5.5 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.